Background The disease burden from interstitial lung diseases (ILDs) is thought to be increasing globally, but there is a ...
End of rarity: the evolving burden of interstitial lung diseases in England – trends from a national population-based cohort study ...
Pulmonary embolism (PE) remains challenging to diagnose and, in particular, to risk stratify. Many patients with low-risk PE ...
Background Inequalities in chronic respiratory diseases persist, yet up-to-date evidence on outcomes remains limited. We described national mortality and exacerbation rates in people with asthma and ...
Background Antimicrobial resistance (AMR) is a global threat for people with chronic lung infection; however, international AMR epidemiology in bronchiectasis and cystic fibrosis (CF) is poorly ...
Background Pulmonary rehabilitation (PR) is the cornerstone of non-pharmacological treatment for chronic obstructive pulmonary disease (COPD), yet fatigue often persists despite rehabilitation. We ...
Progressive pulmonary fibrosis (PPF) is not merely a diagnostic umbrella; it is a continuous, irreversible cascade of fibroproliferation that carries a mortality rate rivalling many aggressive ...
Diarrhoea is the primary cause of nintedanib discontinuation in idiopathic pulmonary fibrosis. We investigated predictors in 100 prospective patients; 46% experienced diarrhoea, defined as common ...
A 62-year-old man with a history of systemic Amyloid light-chain (AL) amyloidosis in prior haematological remission presented with progressive dyspnoea and non-productive cough. He denied haemoptysis, ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...
A 65-year-old male, who does not smoke, with a history of right lower lobectomy for carcinoid tumour 15 years prior, was referred for persistent, unexplained cough over 12 months. This was ...
Background Disease modifying therapies for progressive fibrotic interstitial lung diseases (F-ILDs) slow physiological decline but have not consistently shown to improve patient-reported symptoms or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results